Hantaviruses cause two disease syndromes in humans. New World agents, including Sin Nombre virus (SNV) and Andes virus (ANDV), cause a highly fatal hantavirus cardiopulmonary syndrome (HCPS) in the Americas, whereas Old World agents, including Hantaan virus (HTNV) and Puumala virus (PUUV), cause a less fatal hemorrhagic fever with renal syndrome (HFRS) in Eurasia. All known outbreaks have been traced to the zoonotic transmission of hantaviruses from their rodent host reservoirs, and human population growth and accelerating climate change may increase the frequency and size of hantavirus outbreaks in the coming decades. At present, no approved anti-hantavirus vaccines and therapeutics are available?their development is challenged by crucial gaps in our understanding of the virus-host molecular interactions that underpin infection, disease, and transmission. Current evidence indicates that human hantavirus disease arises from non-cytolytic viral infection and replication in capillary endothelial cells, and their attendant dysregulation. However, the molecular basis of endothelial cell infection, including the identities of essential receptor(s) for hantavirus entry, remains poorly understood. This proposal is centered on our recent discovery of protocadherin-1 (PCDH1), a member of the cadherin superfamily expressed in lung endothelial and epithelial cells, as a novel and critical candidate receptor for hantaviruses in endothelial cells. Our overall goals are to define the molecular mechanism by which PCDH1 mediates hantavirus entry and infection of endothelial cells; investigate the implications of this proposed virus?receptor interaction for hantavirus virulence and pathogenesis in vivo; determine its utility as a target for the development of antiviral therapeutics; and explore its potential role as a host barrier that influences hantavirus host range.

Public Health Relevance

New World hantaviruses, including Sin Nombre virus and Andes virus, cause a highly fatal disease in hu- mans, hantavirus cardiopulmonary syndrome, for which no FDA-approved vaccines or treatments are avail- able. We have recently identified a crucial factor in human and animal cells that these viruses need for in- fection. By understanding how exactly how hantaviruses exploit this factor, we expect to learn more how these viruses cause disease. Our work will also determine if this factor can be targeted by drugs to protect against hantavirus infection, and will provide information crucial to the design and development of these drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI132633-01
Application #
9367734
Study Section
Virology - A Study Section (VIRA)
Program Officer
Repik, Patricia M
Project Start
2017-07-01
Project End
2022-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine, Inc
Department
Type
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461